Association of Abnormal Elevations in IFIT3 With Overactive Cyclic GMP‐AMP Synthase/Stimulator of Interferon Genes Signaling in Human Systemic Lupus Erythematosus Monocytes

Increasing evidence indicates that the cyclic GMP‐AMP synthase/stimulator of interferon genes (cGAS/STING) signaling pathway has a critical pathogenic role in systemic lupus erythematosus (SLE). Expression levels of the interferon (IFN)–inducible gene IFIT3 are elevated in SLE patients. However, it is still not clear how IFIT3 contributes to the pathogenesis of SLE. This study was undertaken to investigate the activation of the cGAS/STING signaling pathway in human SLE monocytes, and to determine how elevated expression of IFIT3 could contribute to overactive cGAS/STING signaling in patients with SLE.

[1]  D. Liggitt,et al.  Ultraviolet B Irradiation Causes Stimulator of Interferon Genes–Dependent Production of Protective Type I Interferon in Mouse Skin by Recruited Inflammatory Monocytes , 2017, Arthritis & rheumatology.

[2]  K. Kalunian,et al.  Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus , 2017, Arthritis & rheumatology.

[3]  J. An,et al.  cGAS Expression in Patients with Systemic Lupus Erythematosus. , 2016 .

[4]  Y. Crow,et al.  Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[5]  C. Fiehn,et al.  Familial chilblain lupus due to a gain-of-function mutation in STING , 2016, Annals of the rheumatic diseases.

[6]  K. Kalunian.  Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells? , 2016, Lupus.

[7]  M. Crow.  Autoimmunity: Interferon α or β: which is the culprit in autoimmune disease? , 2016, Nature Reviews Rheumatology.

[8]  D. Pisetsky,et al.  The Alarmin Properties of DNA and DNA-associated Nuclear Proteins. , 2016, Clinical therapeutics.

[9]  K. Kalunian,et al.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study , 2016, Annals of the rheumatic diseases.

[10]  Zhijian J. Chen,et al.  Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases , 2015, Proceedings of the National Academy of Sciences.

[11]  R. Maciuca,et al.  A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) , 2015, Annals of the rheumatic diseases.

[12]  J. An,et al.  Cutting Edge: Antimalarial Drugs Inhibit IFN-β Production through Blockade of Cyclic GMP-AMP Synthase–DNA Interaction , 2015, The Journal of Immunology.

[13]  C. Mohan,et al.  Suppression of systemic autoimmunity by the innate immune adaptor STING , 2015, Proceedings of the National Academy of Sciences.

[14]  E. Janssen,et al.  STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells , 2014, The Journal of Immunology.

[15]  T. Molina,et al.  Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. , 2014, The Journal of clinical investigation.

[16]  G. Barber,et al.  Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on STING , 2014, The Journal of Immunology.

[17]  Ha Won Kim,et al.  Activated STING in a vascular and pulmonary syndrome. , 2014, The New England journal of medicine.

[18]  M. Crow.  Type I Interferon in the Pathogenesis of Lupus , 2014, The Journal of Immunology.

[19]  Zhijian J. Chen,et al.  The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. , 2014, Molecular cell.

[20]  J. Kahlenberg,et al.  Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease , 2013, The Journal of Immunology.

[21]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA , 2013, Science.

[22]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[23]  M. Gilliet,et al.  Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. , 2012, Blood.

[24]  G. Barber,et al.  Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. , 2012, Immunity.

[25]  Wei Chen,et al.  IFN-Induced TPR Protein IFIT3 Potentiates Antiviral Signaling by Bridging MAVS and TBK1 , 2011, The Journal of Immunology.

[26]  K. Zoon,et al.  Identification of Alpha Interferon-Induced Genes Associated with Antiviral Activity in Daudi Cells and Characterization of IFIT3 as a Novel Antiviral Gene , 2010, Journal of Virology.

[27]  W. Reeves,et al.  Monocyte and Macrophage Abnormalities in Systemic Lupus Erythematosus , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[28]  T. Heidmann,et al.  Trex1 Prevents Cell-Intrinsic Initiation of Autoimmunity , 2008, Cell.

[29]  Yue-ying Gu,et al.  Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells , 2008, Arthritis research & therapy.

[30]  D. Barnes,et al.  Trex1 Exonuclease Degrades ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune Disease , 2007, Cell.

[31]  J. Lieberman,et al.  Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus , 2007, Nature Genetics.

[32]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[33]  D. Furst,et al.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[34]  M. Peterson,et al.  Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .

[35]  C. Bao,et al.  Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray , 2003, Genes and Immunity.

[36]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[37]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[39]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[40]  D. Isenberg,et al.  Systemic lupus erythematosus , 1956, The Lancet.

[41]  L. Lumbroso-Le Rouic,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .

[42]  T. Brannagan,et al.  Polymyositis and dermatomyositis , 2002 .

[43]  A. Bohan,et al.  Polymyositis and dermatomyositis (first of two parts). , 1975, The New England journal of medicine.